一种具有高效光热和光动力学效果的双功能半氨酸材料,用于瘤治疗
Minglu Zhang1,2, Shuo Wang1, Yueping Bai1
1State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Key Laboratory of Molecular Drug Research and KLMDASR of Tianjin, Nankai University, Tongyan Road, Haihe Education Park, Tianjin, 300350, China.
Advanced healthcare materials
|December 9, 2023
概括
研究人员开发了Rh-BI,一种新的有机光学剂,用于联合光热疗法 (PTT) 和光动力疗法 (PDT). 这种双重作用的方法显示,通过增强光子利用率和克服个体治疗的局限性,对有效的抗瘤治疗有很大的希望.
科学领域:
- 生物医学工程 生物医学工程
- 材料科学 材料科学 材料科学
- 摄影化学的使用.
背景情况:
- 小有机分子提供协同光热疗法 (PTT) 和光动力疗法 (PDT) 以提高抗瘤功效.
- 开发双功能光敏剂 (PSs) 以实现高效的协同光疗仍然是癌症治疗的一个重大挑战.
研究的目的:
- 设计和合成一种名为Rh-BI的新型[c,d]替代的半氨酸,作为双功能的PTT-PDT剂.
- 为了研究光热转换效率,光动力学效应和Rh-BI的抗瘤疗效在体外和体内.
主要方法:
- 合成Rh-BI,一种含有[c,d]单元的半氨酸衍生物.
- 光热转换效率和摩尔灭绝系数的表征.
- 在808nm激光照射下对癌细胞系进行体外细胞毒性测定.
- 在4T1瘤携带小鼠体内抗瘤疗效评估.
主要成果:
- 通过抑制光,Rh-BI显示出高光热转换效率为41.67%.
- 该化合物表现出高的摩尔灭绝系数 (13.58 × 104 M-1cm-1),增强了光动力学效应.
- 在体外研究显示显著的光毒性,IC50值低至≈0.5μM.
- 在体内实验成功抑制了4T1瘤携带小鼠的瘤生长.
结论:
- Rh-BI是一种有效的双功能PTT-PDT光学剂,基于半氨酸骨干.
- 调节结合系统是开发用于瘤治疗的先进光学材料的可行策略.
- 开发的药物显示出在癌症治疗中协同光疗的前景.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.


